ArticleBMJ open2022

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).

Hiroshi Nomoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.